INCENTIVE COMPENSATION (Tables)

12 Months Ended

Dec. 25, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of Compensation Cost and Income Tax Benefit

Compensation costs and the income tax benefit recognized for our stock-based compensation arrangements are included below:

	2022		2021		2020
	(In thousands)
Equity-based awards compensation cost:
Cost of sales	$	959	$	3,209	$	838
Selling, general and administrative expense	5,904		7,420		1,938
Total cost	6,863		10,629		2,776
Income tax benefit	1,671		2,587		676
Net cost	$	5,192	$	8,042	$	2,100
Liability-based awards compensation cost:
Selling, general and administrative expense	$	1,773	$	7,715	$	1,081
Income tax benefit	432		1,878		263
Net cost	$	1,341	$	5,837	$	818

Schedule of RSU Activity

The Company’s RSU activity is included below:

	2022			2021			2020
	Number	Weighted Average Milestone Date Fair Value(a)		Number	Weighted Average Milestone Date Fair Value(a)		Number	Weighted Average Milestone Date Fair Value(a)
	(In thousands, except weighted average fair values)
Equity-based RSUs:
Outstanding at beginning of year	554	$	20.40	584	$	22.12	926	$	24.04
Transferred to liability-based awards	—	—		(8)	23.53		(200)	26.91
Granted	405	23.88		817	21.58		249	28.14
Vested	(266)	23.25		(153)	19.48		(66)	24.93
Forfeited awards reinstated (forfeited)	300	23.52		(686)	23.44		(325)	25.95
Outstanding at end of year	993	$	22.00	554	$	20.40	584	$	22.12

	2022			2021			2020
	Number	Weighted Average Milestone Date Fair Value(a)		Number	Weighted Average Milestone Date Fair Value(a)		Number	Weighted Average Milestone Date Fair Value(a)
	(In thousands, except weighted average fair values)
Liability-based RSUs:
Outstanding at beginning of year	574	$	27.55	267	$	19.35	143	$	32.97
Transferred from equity-based awards	—	—		8	23.53		200	26.91
Granted	269	22.09		358	21.61		135	29.47
Vested	(139)	27.55		(59)	20.10		(211)	16.04
Forfeited	(327)	24.71		—	—		—	—
Outstanding at end of year	377	$	23.80	574	$	27.55	267	$	19.35

(a)The milestone date fair value is either the closing price of the Company’s common stock on the grant date for equity-based awards or the closing price of a share of the Company’s common stock on the respective milestone date for cash-based liability-based awards (i.e., grant date, vesting date, forfeiture date or financial reporting date).